SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The promise of molecular science in brain health. What breakthroughs are anticipated in the next 20 years?

Hainsworth, AH; Blackburn, TP; Bradshaw, EM; Elahi, FM; Gorelick, PB; Isaacs, J; Wallin, A; Williams, SCR (2024) The promise of molecular science in brain health. What breakthroughs are anticipated in the next 20 years? Cerebral Circulation, Cognition and Behavior, 7. p. 100364. ISSN 2666-2450 https://doi.org/10.1016/j.cccb.2024.100364
SGUL Authors: Hainsworth, Atticus Henry Isaacs, Jeremy

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview
[img] Microsoft Word (.docx) Accepted Version
Available under License Creative Commons Attribution.

Download (584kB)

Abstract

Brain health means optimal physiological brain function across the normal life-course. It encompasses not only healthy brain aging but also brain diseases, their diagnosis and treatment. In all these areas, molecular science has advanced our understanding. This multi-disciplinary review combines viewpoints from laboratory science, clinical medicine and the bioscience industry. First, we review the advances that molecular science has brought to brain health in the past twenty years. These include therapeutic antibodies for CNS diseases (multiple sclerosis, Alzheimer disease) and the dramatic introduction of RNA-targeted therapeutics. Second, we highlight areas where greater molecular understanding is needed. Salient examples are the relation of brain structure to cognitive symptoms, and molecular biomarkers for diagnosis, target discovery and testing of interventions. Finally, we speculate on aspects of molecular science that are likely to advance brain health in the next twenty years. These include: cell senescence and chronobiology; gene editing (notably, CRISPR) and RNA targeting (RNA interference, miRNA manipulation); brain-immune interactions; novel drug targets (AQP4, HIF1, Toll-like receptors); and novel chemistry to make new drugs (molecular machines, quantum molecular modelling and “click” chemistry). Early testing of the relationships between molecular pathways and clinical manifestations will drive much-needed breakthroughs in neurology and psychiatry.

Item Type: Article
Additional Information: © 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
SGUL Research Institute / Research Centre: ?? 61 ??
Journal or Publication Title: Cerebral Circulation, Cognition and Behavior
ISSN: 2666-2450
Dates:
DateEvent
24 August 2024Published
22 August 2024Published Online
19 August 2024Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
MR/R005567/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/T033371/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
PG/20/10397British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
SP/F/22/150042British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
AS-DTC-23-004UK Alzheimer's SocietyUNSPECIFIED
20140901Alzheimer's Drug Discovery Foundationhttp://dx.doi.org/10.13039/100002565
1RF1AG058852National Institute on Aginghttp://dx.doi.org/10.13039/100000049
1R21AG073882National Institute on Aginghttp://dx.doi.org/10.13039/100000049
R01AG067581National Institute on Aginghttp://dx.doi.org/10.13039/100000049
5R01AG076018National Institute on Aginghttp://dx.doi.org/10.13039/100000049
PF-RCE-1948Parkinson's Disease Foundationhttp://dx.doi.org/10.13039/100001288
IK2CX002180U.S. Department of Veterans Affairshttp://dx.doi.org/10.13039/100000738
UNSPECIFIEDRainwater Charitable Foundationhttp://dx.doi.org/10.13039/100016608
UNSPECIFIEDChan Zuckerberg Initiativehttp://dx.doi.org/10.13039/100014989
UNSPECIFIEDLarry L. Hillblom Foundationhttp://dx.doi.org/10.13039/100001167
UNSPECIFIEDRockefeller Philanthropy AdvisorsUNSPECIFIED
UNSPECIFIEDFriedman Brain InstituteUNSPECIFIED
UNSPECIFIEDRonald M. Loeb Center for Alzheimer's DiseaseUNSPECIFIED
UNSPECIFIEDNew Vision ResearchUNSPECIFIED
7RF1AG072490-02National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
UNSPECIFIEDBayerhttp://dx.doi.org/10.13039/100004326
UNSPECIFIEDWellcome Trusthttp://dx.doi.org/10.13039/100004440
UNSPECIFIEDNIHR Maudsley Biomedical Research Centrehttp://dx.doi.org/10.13039/100019418
URI: https://openaccess.sgul.ac.uk/id/eprint/116753
Publisher's version: https://doi.org/10.1016/j.cccb.2024.100364

Actions (login required)

Edit Item Edit Item